Physician profile
Kelley Moon
NPI 1255366035
$8,057.20
in general payments reported to CMS, 2019-2025
44 companies · $920 in 2025
The $920 reported for 2025 was more than what 87% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,211 · 2020: $1,132 · 2021: $1,031 · 2022: $1,204 · 2023: $1,347 · 2024: $1,213 · 2025: $920.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,384 · Education: $95.76.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,383.58 |
| Education | $95.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,572.06 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Glaxosmithkline, LLC. | $892.78 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Lilly USA, LLC | $678.47 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Amgen INC. | $628.79 | 2019-2025 | Otezla, Repatha, Repatha |
| Pfizer INC. | $502.87 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $497.47 | 2019-2025 | Jardiance, Synjardy |
| Abbvie INC. | $424.04 | 2021-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $358.94 | 2022-2025 | |
| Novo Nordisk INC | $330.10 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $300.11 | 2020-2024 | Caplyta |
| Merck Sharp & Dohme LLC | $255.78 | 2019-2022 | |
| Paratek Pharmaceuticals, INC. | $194.79 | 2021-2022 | |
| Allergan, INC. | $191.32 | 2019-2021 | |
| Teva Pharmaceuticals USA, INC. | $170.13 | 2020-2024 | Ajovy, Austedo Xr |
| Otsuka America Pharmaceutical, INC. | $132.19 | 2019-2024 | Rexulti |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kelley Moon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.